Our study also demonstrated that NFE2L3 expression was associated with patient survival in multiple ICB cohorts, and that knockdown of NFE2L3 improved the effect of ICB treatment for colon cancer in the Kearney 2018 NK_10 cohort. This evidence concerns the gene NFE2L3 and malignant colon neoplasm.